Generic Name: Cyproterone Acetate 2mg + Ethinyl Estradiol 35mcg
Manufacturer/Distributor: Renata Limited
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Indications of Giane 35
Giane 35, a combination of two hormone drugs, is used to treat polycystic ovarian syndrome (PCOS) symptoms include excessive hair growth (hirsutism), acne, and irregular menstrual cycles. Avoid using any other contraceptive pills since it also functions as a contraceptive.
Pharmacology
Cyproterone is a steroid that has antiandrogenic, progestogenic, and antigonadotrophic properties. Its antiandrogenic action is achieved by inhibiting androgen receptors. It also has a negative feedback impact on the hypothalamic-pituitary-ovarian circuits, which decreases androgen production. The estrogen component (Ethinylestradiol) raises levels of sex hormone-binding globulin (SHBG) and consequently lowers androgen levels in the blood. SHBG levels are not reduced by cyproterone.
Cyproterone, when administered alone in women, causes menstrual cycle disruptions, which are prevented when coupled with Ethinylestradiol. When taken in a cyclic pattern, this pill offers the extra benefit of preventing ovulation and possible pregnancy.
After oral administration, the components of this tablet are promptly absorbed. After 6 to 12 days of daily dosage, a 4-fold rise in plasma levels occurs due to Cyproterone's lengthy terminal half-life. Long-term treatment with this substance (36 months) had no discernible effect on lipid metabolism. There was a tendency toward higher plasma cholesterol and triglyceride levels. Low-density lipoprotein (LDL) levels fell slightly, but high-density lipoprotein (HDL) levels rose (HDL).
Dosage & Administration
This tablet should not be prescribed solely for its contraceptive properties. If patient compliance is uncertain and contraception is necessary, then a supplementary nonhormonal contraceptive method should be considered.
Interaction of Giane 35
Ampicillin, analgesics, antihistamines, antimigraine preparations, Chloramphenicol, Griseofulvin, Isoniazid, Neomycin, Nitrofurantoin, Penicillin V, Phenylbutazone, Sulfonamides, and Tetracycline may impair the effectiveness of this pill and raise the risk of breakthrough bleeding if taken together.
When anticoagulants are used with estrogen/progestogen combos, the anticoagulant impact may be reduced. Ampicillin, analgesics, antihistamines, antimigraine preparations, Chloramphenicol, Griseofulvin, Isoniazid, Neomycin, Nitrofurantoin, Penicillin V, Phenylbutazone, Sulfonamides, and Tetracycline may impair the effectiveness of this pill and raise the risk of breakthrough bleeding if taken together.
When anticoagulants are used with estrogen/progestogen combos, the anticoagulant impact may be reduced. Anti-diabetic medicine may need to be adjusted for diabetics who use estrogen/progestogen combos. It has been observed that taking vitamin C (ascorbic acid) with estrogen/progestogen combinations causes a substantial increase in plasma Ethinylestradiol levels.
Before starting therapy, be sure you're not pregnant. Feminization of male fetuses has happened in animal studies and may occur in humans due to the antiandrogenic effect of this pill.
Contraindications
Side Effect
Bleeding, dizziness, depression, weight gain, headache, edema, breast discomfort, lactation, blood clot, and gallstones are all common adverse effects.
Pregnancy & Lactation
The kids of women who used estrogen/progestogen combos in early pregnancy have been documented to develop fetal defects. As soon as you suspect pregnancy, rule it out. It's possible that using estrogen/progestogen combos when a woman is breastfeeding her baby isn't a good idea. The hormonal components are expelled in breast milk, which might affect the amount and quality of the product. The long-term consequences on a child's development remain unknown. Fluid retention, as well as epilepsy, are possible side effects of this medication.
Precautions & Warnings
Predisposing Factors for Coronary Artery Diseases: The use of estrogen or progestogen combinations has been reported as an additional risk factor in women with predisposing factors for coronary artery disease (such as cigarette smoking, hypertension, hypercholesterolemia, obesity, diabetes, and increasing age). After the age of 35, estrogen or progestogen combinations should only be considered in rare circumstances and after both the patient and the physician have carefully analyzed the risk/benefit ratio.
Thromboembolic and cardiovascular diseases such as thrombophlebitis, pulmonary embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and retinal thrombosis should be stopped as soon as possible. In situations that predispose to venous stasis and vascular thrombosis, such as immobilization following accidents or confinement to bed during long-term sickness, the use of estrogen/progestogen-combination products should be avoided.
Patients with essential hypertension who have well-controlled blood pressure may be administered the medication, but only under strict monitoring. If a substantial increase in blood pressure develops in previously normotensive or hypertensive individuals at any point during the drug's treatment, the medication must be stopped.
Storage Conditions
Keep away from light and moisture in a cool, dry area (below 30° C). Keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.